Characteristics of patients with type 2 diabetes mellitus (CVD-RNDR)

Study identifier:D1690R00048

ClinicalTrials.gov identifier:NCT03694470

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Retrospective study to describe characteristics of patients with type 2 diabetes mellitus who were initiating use or treatment with sodium-glucose co-transporter-2 inhibitors and other diabetes medications (other glucose lowering drugs) in 2015-17 based on National Russian Diabetes Registry data

Medical condition

Type 2 Diabetes

Phase

N/A

Healthy volunteers

Study drug

Sex

All

Actual Enrollment

10000

Study type

Observational

Age

N/A

Date

Study Start Date: 15 Apr 2018

Primary Completion Date: 30 Jun 2018

Study Completion Date: 30 Jun 2018

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jun 2019 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

Location

Research site

Moscow, Russian Federation

Arms	Assigned Interventions

Documents available

CSR Synopsis
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

information.center@astrazeneca.com